Provider Briefing: Avanafil Availability in 2026

As a prescriber, you may have patients reporting difficulty filling Avanafil (Stendra) prescriptions. While Avanafil is not listed on the FDA's official drug shortage database, real-world availability at retail pharmacies remains inconsistent. This guide provides a clinical and practical overview of the current landscape to help you manage patient expectations and optimize treatment access.

Timeline: Avanafil's Market Evolution

Understanding how Avanafil arrived at its current availability status helps frame the clinical conversation:

• April 2012: FDA approves Stendra (avanafil) for erectile dysfunction — the first new PDE5 inhibitor approved since Cialis (2003)
• 2012–2023: Stendra remains brand-only with limited market penetration. Sildenafil and Tadalafil generics dominate the PDE5 inhibitor market.
• June 2024: FDA approves the first generic avanafil (Hetero Labs Ltd) in 50 mg, 100 mg, and 200 mg tablet strengths
• October 2024: Camber Pharmaceuticals launches an AB-rated generic avanafil
• 2025–2026: Generic availability gradually increases, but pharmacy stocking remains inconsistent due to low demand relative to sildenafil and tadalafil

Petros Pharmaceuticals (current Stendra rights holder) has also pursued an OTC switch pathway through the FDA's Additional Conditions for Nonprescription Use (ACNU) framework, though this has not been completed as of early 2026.

Prescribing Implications

Avanafil's clinical profile offers distinct advantages that make it a reasonable choice for certain patients:

Rapid Onset

Avanafil has the fastest onset of action among approved PDE5 inhibitors, with efficacy demonstrated as early as 15 minutes after dosing. This is particularly relevant for patients who prioritize spontaneity and find the 30- to 60-minute wait for sildenafil or tadalafil (as-needed dosing) to be a barrier.

Selectivity and Tolerability

Avanafil demonstrates greater selectivity for PDE5 relative to other phosphodiesterase isoforms (PDE1, PDE6, PDE11) compared to sildenafil and vardenafil. This may translate to a more favorable side effect profile in some patients — particularly fewer visual disturbances (a PDE6-mediated effect) and potentially fewer muscle aches (PDE11-mediated).

Dosing

The recommended starting dose is 100 mg, taken approximately 30 minutes before sexual activity. The dose may be adjusted to 50 mg or 200 mg based on response and tolerability. Maximum frequency is once daily. With moderate CYP3A4 inhibitors (diltiazem, verapamil, fluconazole, erythromycin), the maximum dose is 50 mg per 24 hours. Avanafil is contraindicated with strong CYP3A4 inhibitors and all nitrate formulations.

For a comprehensive review of drug interactions, see: Avanafil Drug Interactions: What to Avoid.

Current Availability Picture

The availability challenge with Avanafil is not a supply chain or manufacturing shortage. Rather, it's a demand-driven stocking gap:

• Low pharmacy shelf presence: Because sildenafil and tadalafil generics account for the vast majority of PDE5 inhibitor prescriptions, many retail pharmacies do not routinely stock avanafil.
• Generic distribution still maturing: While two generic manufacturers (Hetero Labs and Camber) have products on the market, wholesaler availability hasn't reached the same ubiquity as other PDE5 generics.
• Chain pharmacy algorithms: Large chain pharmacies use automated inventory systems that stock based on dispensing volume. Avanafil's low volume means it often doesn't meet the threshold for automatic restocking.

Most pharmacies can order generic avanafil through their wholesaler with 1- to 2-day turnaround. Proactively advising patients to request an order (rather than expecting it to be on the shelf) can significantly improve fill rates.

Cost and Access Considerations

Cost remains a significant barrier for many patients:

• Brand Stendra: Approximately $400–$700 for 6–10 tablets
• Generic avanafil (with discount card): $97–$230 for 10 tablets (GoodRx, SingleCare)
• Generic avanafil (retail without discount): Up to $1,485 for 30 tablets
• Insurance coverage: Most Medicare Part D plans and many commercial plans do not cover avanafil. When covered, prior authorization is standard, and step therapy through sildenafil or tadalafil is typically required.

For patients who are cost-sensitive, it is worth noting that generic sildenafil can be obtained for as little as $3–$10 per tablet and generic tadalafil for $3–$15 per tablet.

Tools and Resources for Providers

Medfinder for Providers enables you to check real-time pharmacy stock levels for avanafil and direct patients to pharmacies that currently have it available. This is particularly useful for:

• Verifying stock before sending a prescription electronically
• Helping patients avoid multiple pharmacy visits
• Identifying independent pharmacies that may stock less common medications

Additional resources:

• Patient savings guide: How to Save Money on Avanafil in 2026
• Patient-facing availability guide: How to Find Avanafil in Stock Near You
• Provider guide to helping patients find stock: How to Help Your Patients Find Avanafil in Stock

Therapeutic Alternatives

When avanafil is not accessible or appropriate, consider these alternatives:

• Sildenafil (Viagra): 25–100 mg as needed, onset 30–60 min, duration 4–6 hours. Widely available, lowest cost generic.
• Tadalafil (Cialis): 5–20 mg as needed or 2.5–5 mg daily. Onset 30–45 min, duration up to 36 hours. Daily dosing option unique in class.
• Vardenafil (Levitra/Staxyn): 5–20 mg as needed, onset 30–60 min, duration 4–6 hours. ODT formulation available.

All PDE5 inhibitors share the same contraindications (nitrates, riociguat) and cautions (alpha-blockers, CYP3A4 inhibitors). Switching within the class is generally straightforward.

For a patient-facing comparison: Alternatives to Avanafil.

Looking Ahead

Several developments may improve Avanafil access in the coming years:

• Additional generic manufacturers: As more companies enter the market, competition should drive prices down and improve wholesale availability.
• Potential OTC switch: Petros Pharmaceuticals' OTC pursuit could eventually eliminate the prescription barrier entirely, which would fundamentally change access dynamics.
• Telehealth expansion: The continued growth of telehealth-based ED prescribing gives patients more pathways to obtain avanafil with home delivery.

Final Thoughts

Avanafil remains a clinically valuable PDE5 inhibitor — its rapid onset and selectivity profile make it an important option for the right patient. The practical challenge is access, not efficacy. By proactively guiding patients to use stock-checking tools like Medfinder, advising them to request pharmacy orders, and discussing cost-saving strategies, you can help more patients successfully fill their prescriptions.

For patients who cannot access Avanafil, the therapeutic alternatives in this class are well-established and highly effective. The goal is ensuring every patient has access to a treatment that works for them.